Fujian Cosunter’s HBV Therapy GST-HG141 Begins Phase II Trial
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the first patient enrollment and...
Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...
Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study
US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...
Lifetech Partners with Jenscare for Structural Heart Disease Devices
China-based Lifetech Scientific Corporation (HKG: 1302) has announced a partnership agreement with compatriot firm Jenscare...
Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval
Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US...
Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results
US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial...
Sanofi Reports Strong Q4 and Full-Year 2022 Financials with 7% Growth
France’s Sanofi (EPA: SAN) released its financial report last week, showing turnover during Q4 and...
Sanner Group Prepares to Open Second Manufacturing Facility in China
Germany-based Sanner Group, a specialist in medical devices and pharma packaging, has announced plans to...
Insilico Medicine Opens AI Biotech Research Center in Abu Dhabi
China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology...
Vertex’s MoDAS System Gains NMPA Approval for Movement Disorder Assessment
China-based Vertex has announced receiving medical device approval from the National Medical Products Administration (NMPA)...
BeiGene Launches Mental Health Program for Cancer Patients
China-based biotech BeiGene (Nasdaq: BGNE; HKG: 6160; SHA: 688235) has announced the launch of a...
AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics
Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have...
Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND)...
Forlong Biotechnology Secures Series A Funding for Protein Drug Development
Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards...
Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06
Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK...
Haisco Pharmaceutical Announces Public Offering for Clinical Studies
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering...
BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review
Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111,...
JunTop Biosciences’ COVID-19 Therapy Mindewei Priced at RMB 795 per Course
Sichuan’s provincial Healthcare Security Administration bureau has notified that Shanghai JunTop Biosciences Co., Ltd’s COVID-19...
Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...
Mabwell’s Novel ADC 9MW2921 Accepted for NMPA Review
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...